ADO and neoplasm: Studies on mice models demonstrated that CD38-expressing tumor cells impair CD8+ T-cell function and proliferation; however, the treatment with ADO receptor antagonists effectively reversed CD38 suppressive effect on tumor infiltrating CD8+ cells indicating that CD38-mediated production of ADO inhibits CD8+ T-cell proliferation through adenosine receptor signaling [91].